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Abstract 
Polycystic ovary syndrome (PCOS) is a common, complex condition that affects up to 18% of reproductive-
aged women, causing reproductive, metabolic and psychological dysfunctions. We performed an overview 
and appraisal of methodological quality of systematic reviews that assessed medical and surgical treatments 
for reproductive outcomes in women with PCOS. Databases (MEDLINE, EMBASE, CINAHL PLUS and 
PROSPERO) were searched on the 15th of September 2017. We included any systematic review that assessed 
the effect of medical or surgical management of PCOS on reproductive, pregnancy and neonatal outcomes. 
Eligibility assessment, data extraction and quality assessment by the Assessing the Methodological Quality 
of Systematic Reviews (AMSTAR) tool were performed in duplicate. We identified 53 reviews comprising 
44 reviews included in this overview; the majority were moderate to high quality. In unselected women with 
PCOS, letrozole was associated with a higher live birth rate than clomiphene citrate (CC), while CC was better 
than metformin or placebo. In women with CC-resistant PCOS, gonadotrophins were associated with a higher 
live birth rate than CC plus metformin, which was better than laparoscopic ovarian drilling (LOD). LOD was 
associated with lower multiple pregnancy rates than other medical treatments. In women with PCOS undergo-
ing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI), the addition of metformin to gonadotro-
phins resulted in less ovarian hyperstimulation syndrome (OHSS), and higher pregnancy and live birth rates 
than gonadotrophins alone. Gonadotrophin releasing hormone (GnRH) antagonist was associated with less 
OHSS, gonadotrophin units and shorter stimulation length than GnRH agonist. Letrozole appears to be a good 
first line treatment and gonadotrophins, as a second line treatment, for anovulatory women with PCOS. LOD 
results in lower multiple pregnancy rates. However, due to the heterogeneous nature of the included popula-
tions of women with PCOS, further larger scale trials are needed with more precise assessment of treatments 
according to heterogeneous variants of PCOS.
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Introduction 
Polycystic ovary syndrome (PCOS) is one of the most 
important dilemmas in reproductive medicine. PCOS is 
a member of the World Health Organization group II 
ovulation disorders, and has a 9-18% prevalence among 
reproductive-aged women (1) and nearly 80% among 
infertile anovulatory women (1, 2). There is an ongoing 
debate related to its definition, aetiology, diagnosis and 
treatment for its clinical phenotypes (3). Since first de-
scribed by Stein and Leventhal (4), a number of reports 
and meetings have suggested diagnostic criteria for this 
condition (3, 5, 6). However, the criteria reported by 
ESHRE/ASRM in Rotterdam in 2003 are most com-
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monly used both in research and clinical care. These 
criteria propose that two out of three domains should 
be present to establish a diagnosis of PCOS. These 
domains are: an-/oligo-ovulation, hyperandrogenism 
(clinical ± biochemical) and polycystic ovary morphol-
ogy on ultrasound examination, with exclusion of other 
causes of hyperandrogenism (6). In 2012, the National 
Institute of Health reinforced the need for identifica-
tion of four phenotypes within the Rotterdam criteria 
in women with PCOS, which refer to the combination 
of diagnostic criteria (7). By using the possible combi-
nations of these criteria, four different phenotypes of 
PCOS are now identified: i. Hyperandrogenism (clini-
cal or biochemical) and chronic anovulation (H-CA), 
ii. Hyperandrogenism and polycystic ovaries on ultra-
sound (PCOm), but with ovulatory cycles (H-PCOm), 
iii. Chronic anovulation and polycystic ovaries without 
hyperandrogenism (CA-PCOm), and iv. Hyperandro-
genism, chronic anovulation and polycystic ovaries 
(H-CA-PCOm). The identification of specific pheno-
types in women with PCOS seems to be justified from 
the metabolic point (3). 
This heterogeneous condition manifests with many 
clinical presentations, including infertility, pregnan-
cy complications, and psychological and metabolic 
features. The reproductive problems associated with 
PCOS consist mainly of menstrual dysfunction, infer-
tility and pregnancy complications. Many treatments 
are proposed by different guidelines for infertility with 
PCOS, and include clomiphene citrate (CC), letrozole 
and gonadotrophins. However, there is a lack of clar-
ity around the relative efficacy of these different treat-
ments. Despite the agreement between most guidelines 
of the importance and priority of lifestyle modification 
in PCOS and weight loss, where women are overweight 
or obese, there are still limited studies that compare 
lifestyle modification and pharmacological drugs for 
reproductive outcomes (8). With regards to pharma-
cological treatment in isolation, CC is recommended 
as first-line treatment for ovulation induction (OI) in 
infertile women with POCS with the alternative treat-
ment, letrozole, which has encouraging results in many 
recent trials (1, 2, 8-10). Although the insulin sensitizer 
metformin has been recently recommended as a first-
line treatment (11), its role and specific indication are 
controversial (1-3). The second-line treatment is usu-
ally recommended as gonadotrophins or laparoscopic 
ovarian drilling (LOD) (2). Additional issues relating 
to treatment of reproductive outcomes which are still 
somewhat controversial include the best time to use 
in vitro fertilization/intracytoplasmic sperm injection 
(IVF/ICSI) in women who failed to become pregnant 
after pharmacological treatment, and the potential 
benefit of modern techniques like in vitro maturation 
(IVM) (2, 3).
The aim of this review was to perform an overview to 
summarize and appraise the content, results and quality of 
systematic reviews that assess medical or surgical treat-
ments for reproductive outcomes in women with PCOS.
Materials and Methods
Inclusion criteria
The Participant, Intervention, Comparison, Outcomes 
and Studies (PICOS) framework was used for this review. 
This overview is part of a larger overview of systematic 
reviews. For this broader overview, we included any sys-
tematic review or meta-analysis where the assessment or 
management of PCOS was the primary focus of the re-
view, either as interventions in PCOS or a comparison of 
women with and without PCOS for a specific outcome. 
Exclusion criteria were studies where PCOS was a sec-
ondary condition assessed as part of a broader topic. For 
this specific overview, we included any systematic review 
that assessed the effect of medical or surgical manage-
ment of PCOS on reproductive outcomes. The specific in-
clusion criteria were: i. Published from 2009 onwards, as 
this was the date of publication of the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRIS-
MA) statement as a guideline for conducting systematic 
reviews (12), ii. Must have included a search strategy that 
contained at least key words or terms, iii. Must include 
the number of identified and included articles, and iv. The 
review needed to conduct some form of quality appraisal 
of the articles. The comparisons term was not applicable 
in this review context. The outcomes assessed were re-
productive outcomes, specifically live birth, clinical preg-
nancy, miscarriage, ovulation, multiple pregnancy, men-
strual cycle frequency, follicular size, pregnancy related 
outcomes (gestational diabetes, pregnancy-induced hy-
pertension and pre-eclampsia), neonatal outcomes, costs 
and side effects. Only articles published in English were 
included. The protocol is registered in the International 
Prospective Register of Systematic Reviews PROSPERO 
(CRD42016052649).
Article selection
A comprehensive database search was conducted on 
the 17th of October 2016, which was last updated on 15th 
September 2017. The following electronic databases 
were used to identify relevant published literature: Med-
line in-process and other non-indexed citations [Ovid 
MEDLINE(R) In-Process & Other Non-Indexed Cita-
tions, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 
1946 to Present]; EMBASE (EBM Reviews - Cochrane 
Database of Systematic Reviews 2005 to September 15, 
2017, EBM Reviews - ACP Journal Club 1991 to Sep-
tember 2017, EBM Reviews - Database of Abstracts 
of Reviews of Effects 1st Quarter 2016, EBM Reviews 
- Cochrane Central Register of Controlled Trials Sep-
tember 2017, EBM Reviews - Cochrane Methodology 
Register 3rd Quarter 2012, EBM Reviews - Health Tech-
nology Assessment 4th Quarter 2016, EBM Reviews - 
NHS Economic Evaluation Database 1st Quarter 2016); 
and CINAHL PLUS. The search strategy is documented 
in Supplementary Appendix 1 (See Supplementary On-
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line Information at www.celljournal.org). This search was 
modified for EMBASE and CINAHL using their subject 
headings instead of the MeSH subject headings. The In-
ternational Prospective Register of Systematic Reviews 
PROSPERO (http://www.crd.york.ac.uk/PROSPERO/) 
was additionally searched on the 15th September 2017 
using the key words “PCOS” or “polycystic ovary syn-
drome”. In addition, experts in the field were asked to 
provide any potentially relevant studies for consideration. 
Two independent reviewers, who were not blinded to the 
names of investigators or sources of publication, identi-
fied and selected the articles that met the inclusion criteria 
(L.J.M, D.H or C.T.T). Disagreements between reviewers 
were discussed and resolved by consensus or arbitration 
with a third reviewer.
Data extraction
All eligible systematic reviews included were examined 
and extracted independently by two reviewers (L.J.M, 
M.G or C.T.T). Disagreements were discussed and re-
solved by consensus or arbitration with a third reviewer. 
The data extracted included information on author(s), 
year, country of author, inclusion criteria, study method-
ology, study outcomes, number of studies identified, num-
ber of participants in the review, whether a meta-analysis 
was conducted, and quality of identified articles in each 
review (as reported by the systematic review authors as 
overall quality of the entire study or evidence or reported 
as unclear if not summarized by the systematic review au-
thors).
Data synthesis
A narrative description of the included reviews was per-
formed. We presented results per reproductive outcome. 
Quality assessment of systematic reviews
All included reviews were evaluated by two independ-
ent reviewers (L.J.M, M.G or C.T.T) using the Assessing 
the Methodological Quality of Systematic Reviews (AM-
STAR) tool (13, 14). Disagreements were discussed and 
resolved by consensus or arbitration with a third review-
er. The AMSTAR tool contains 11 items to appraise the 
methodological aspects of the systematic reviews. Each 
item was scored 1 for “yes” and 0 for “no” or “not appli-
cable” with a total score range from 0 to 11. The methodo-
logical quality for each review was classified as low [≤ 3], 
moderate [4-7] and high [8-11] (15) .
Results
Characteristics of included reviews 
The search yielded 978 citations, with 60 citations iden-
tified from PROSPERO and one citation identified from 
expert assessors, for a total of 1039 citations. There were 
831 citations that remained after removal of duplicates. 
Based on a priori selection criteria, screening for title or 
abstract identified 276 articles for assessment of the full 
text. Of these, 128 articles were excluded for the follow-
ing: not conducting quality assessment, not in English, 
no search terms detailed or no identified search strategy 
(Supplementary Appendix 2) (See Supplementary Online 
Information at www.celljournal.org). We included 139 
full-text articles for our final analysis, of which 53 articles 
were related to the theme of medical or surgical treatment 
on reproductive outcomes in PCOS, with the remaining 
eligible articles assessed in separate overviews of system-
atic reviews and excluded from this specific review. These 
53 articles comprised 44 reviews (Fig.1).
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Fig.1: Study selection.
The characteristics of these reviews are summarized 
in Supplementary Appendix 3 (See Supplementary On-
line Information at www.celljournal.org). The number 
of included studies in each review ranged between none 
(16, 17) and 66 (18). The type of included studies in each 
review was only randomised controlled trials (RCTs) in 
22 reviews (16, 18-38), RCTs and crossover trials until 
first inclusion in 11 reviews (17, 33, 39-47), RCTs and 
systematic reviews of RCTs in two reviews (48, 49), any 
study design in two reviews (50, 51), any study with con-
trol group in three reviews (52-54), RCTs and prospec-
tive studies in one review (55) and not stated in three re-
views (56-58). Participants in the included reviews were 
treatment-naive women in two reviews (27, 28), women 
resistant to CC in six reviews (19, 23, 29, 32, 33, 56), 
women whose treatment status was undefined in 32 re-
views (16-18, 20-22, 24-26, 30, 31, 35-42, 44-51, 55, 57, 
59), pregnant women with PCOS in four reviews (52-54, 
58), adolescents with PCOS (11-19 years old) in one re-
view (34), and women with PCOS not trying to conceive 
in one review (43). Twenty-two reviews were conducted 
according to prior guidelines for conducting systematic 
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reviews such as PRISMA, Meta-analyses Of Observa-
tional Studies in Epidemiology (MOOSE), Quality of Re-
porting of Meta-analyses (QUORUMS) or Cochrane (16, 
17, 19, 23, 25, 27, 29, 32, 34, 36, 39-46, 50, 51, 58, 59). 
Meta-analyses were performed in 39 reviews (18-32, 34-
43, 45-50, 52-59). The systematic reviews did not apply 
language restrictions in 28 reviews (16, 17, 19, 20, 24-26, 
28, 29, 34, 36, 38-47, 50, 53-56, 58, 59), restricted the 
search to articles in English in 12 reviews (18, 21, 22, 27, 
32, 33, 35, 37, 48, 49, 52, 57), restricted the search to ar-
ticles in English and Chinese in two reviews (30, 31) and 
did not state if language restrictions were applied in two 
reviews (23, 51). The quality of included studies in each 
review was not reported by authors or was not able to be 
easily interpreted in 31 reviews (16, 17, 20-29, 32, 36, 
38, 39, 42, 43, 45-47, 50-59), low or insufficient in eight 
reviews (18, 31, 34, 35, 37, 40, 41, 44), low to moderate 
in two reviews (19, 48) and low to high in three reviews 
(30, 33, 49) 
Quality of included reviews
The quality of the included reviews are presented in 
Supplementary Appendix 4 (See Supplementary On-
line Information at www.celljournal.org). Seven re-
views were of low quality (28, 30, 33, 36, 51, 52, 58), 
22 reviews were of moderate quality (16, 20-27, 31, 32, 
35, 37, 38, 40, 50, 53-57, 59) and 15 reviews were of 
high quality (17-19, 29, 34, 39, 41-49). Twenty reviews 
had pre-specified their clinical question and inclusion 
criteria (16-19, 29, 33, 34, 39-49, 55, 59). Nineteen re-
views conducted study selection and data extraction in 
duplicate (17-19, 21, 23, 26, 27, 29, 32, 34, 37, 39, 
42-45, 50, 55, 57). Twenty-eight reviews conducted a 
comprehensive literature search (16-19, 21, 24-26, 28-
31, 34, 38-49, 53, 54, 59). Twenty reviews included 
grey literature searches (16, 17, 19, 25, 26, 29, 34, 38-
47, 53, 54, 59). Twenty-four reviews listed included 
and excluded studies (16, 17, 19, 23-27, 29, 32, 34, 38, 
39, 41-46, 48-50, 57, 59). Forty reviews described the 
characteristics of the included studies (18-29, 32-59). 
Thirty-eight reviews assessed study quality (16-27, 29-
35, 37-50, 54, 56, 57, 59, 60). Nineteen reviews used 
the scientific quality of their included studies in for-
mulating results (18, 20-22, 24, 25, 29, 31, 32, 34, 35, 
39, 40, 45-49, 57). Thirty-seven reviews combined the 
studies using appropriate methods (18-32, 35-43, 45, 
46, 48-50, 52-59). Twenty-two reviews addressed the 
risk of reporting bias, and used a statistical test where 
appropriate (16-19, 32, 34, 35, 37-39, 41-44, 46, 47, 
50, 52, 53, 55, 56, 58). Seven reviews addressed the 
potential for conflict of interest (16, 17, 29, 43, 47-49).
Types of interventions
Letrozole 
Six reviews (three high quality (19, 39, 49) and three 
moderate quality (20, 27, 32) assessed interventions that 
contained letrozole, comprising a total of 89 trials and 14 
008 participants. Of these, five assessed letrozole ± other 
OI drugs versus OI drugs, including letrozole alone (20, 
27, 32, 39, 49) and one assessed letrozole versus LOD 
(19). The populations studied were women with PCOS 
who were treatment-naïve (27), CC resistant (32), or 
treatment-naïve ± CC resistant or unknown treatment sta-
tus (20, 39, 49). 
The meta-analyses reported statistically significant re-
sults for higher live birth, pregnancy and ovulation after 
letrozole compared to CC followed by timed intercourse 
in overall women with PCOS, and higher live birth and 
pregnancy after letrozole in women with PCOS and body 
mass index (BMI) >25 kg/m2 (20, 27, 39, 49). In women 
with CC resistance, letrozole with or without metformin 
resulted in higher live births compared to CC with met-
formin (32, 39), letrozole resulted in higher pregnancy 
and ovulation than anastrozole and higher ovulation 
than LOD (49). Long-term letrozole (10 days) resulted 
in higher pregnancy than short-term letrozole (5 days) 
(Tables 1, 2) (49). 
Table 1: Results of main medical interventions
Review Population Outcomes assessed Comparison Outcomes with significant results
Letrozole
Abu Hashim et al. (32), 
2015
CC resistant PCOS Live birth 
Pregnancy 
Ovulation 
Miscarriage 
Multiple  pregnancy 
OHSS
CC+metformin vs.  Letrozole Live birth/woman OR: 0.21, 95% CI: 0.05 to 0.87
Franik et al. (39), 2014 PCOS, reproductive age Live birth 
Pregnancy 
Miscarriage 
Multiple  pregnancy 
OHSS
Letrozole vs. CC (BMI >25 kg/m2) 
Letrozole vs. CC (with or without adjuncts 
followed by timed intercourse)
Letrozole vs. CC  (with or without adjuncts 
followed by IUI)  
Letrozole vs. CC (overall with or without 
adjuncts followed by timed intercourse) 
Letrozole vs. CC+rFSH and rFSH only
Letrozole+metformin vs. CC+metformin 
Live birth/woman
Live birth/woman
Pregnancy/woman
Pregnancy/woman
Pregnancy/woman
Live birth/woman
OR: 1.67, 95% CI: 1.31 to 2.11
OR: 1.64, 95% CI: 1.32 to 2.04
OR: 1.71, 95% CI: 1.30 to 2.25
OR: 1.40, 95% CI: 1.18 to 1.65
OR: 1.66, 95% CI: 1.23 to 2.22
OR: 4.5, 95% CI: 1.09 to 18.50
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Table 1: Continued
He and Jiang (20), 2011 PCOS Pregnancy 
Ovulation 
Miscarriage 
Multiple pregnancy 
OHSS 
Mature follicles
Letrozole vs. CC
Letrozole vs. CC
Mature follicles/cycle
Ovulation/cycle
SMD: 1.41, 95% CI: 1.54 to 1.28
RR: 1.29, 95% CI: 1.12 to 1.49
Misso et al. (49), 2012 PCOS Live birth 
Pregnancy 
Ovulation 
Miscarriage 
Multiple pregnancies 
Adverse events 
Cost effectiveness
Letrozole long-term (10 days) vs. Letrozole 
short-term (5 days) 
Letrozole vs. Anastrozole
Letrozole vs. Anastrozole
Letrozole vs. CC
Letrozole vs. LOD
Pregnancy/cycle
Ovulation/cycle
Pregnancy/woman
Ovulation/woman
Ovulation/cycle
Higher in long-term (10 days) 
Higher in letrozole
Higher in letrozole
OR: 2.90, 95% CI: 1.72 to 4.88
Higher in letrozole
Roque et al. (27), 2015 PCOS (therapy naïve) Live birth 
Clinical pregnancy 
Ovulation 
Miscarriage 
Multiple pregnancy
Letrozole vs. CC
Letrozole vs. CC
Live birth/woman
Pregnancy/woman
RR: 1.55, 95% CI: 1.26 to 1.90 
RR: 1.38, 95% CI: 1.05 to 1.83
CC
Abu Hashim et al. (32), 
2015
CC resistant PCOS Live birth 
Pregnancy 
Ovulation 
Miscarriage 
Multiple pregnancy 
OHSS
CC+metformin vs. Gonadotrophins   
CC+metformin vs. Gonadotrophins   
CC+metformin vs. CC + NAC 
CC+metformin vs. Gonadotrophins   
CC+metformin vs. CC + NAC 
Live birth/woman 
Ovulation/woman 
Ovulation/woman 
Pregnancy/woman 
Pregnancy/woman
OR: 0.33, 95% CI: 0.13 to 0.85 
OR: 0.25, 95% CI: 0.15 to 0.41 
OR: 8.93, 95% CI: 4.61 to 17.32 
OR: 0.45, 95% CI: 0.27 to 0.75 
OR: 5.28, 95% CI: 1.91 to 14.62
Brown and Farquhar 
(46), 2017
WHO group 2 
anovulation
Live birth 
Pregnancy 
Ovulation 
Miscarriage 
Multiple pregnancy 
OHSS 
Adverse effects
CC vs. Placebo CC vs. Gonadotrophins 
CC vs. Gonadotrophins 
CC 5 day vs. CC 10 day 
CC 5 day vs. CC 10 day 
CC+DEX vs. CC  
Early CC vs. late CC 
CC+OCP vs. CC
Pregnancy/woman 
Live birth/woman 
Pregnancy/woman 
Live birth/woman 
Pregnancy/woman 
Pregnancy/woman 
Pregnancy/woman 
Pregnancy/woman
OR: 5.91, 95% CI: 1.77 to 19.68 
OR: 0.64, 95% CI: 0.41 to 0.98 
OR: 0.61, 95% CI: 0.40 to 0.93 
OR: 0.10, 95% CI: 0.02 to 0.45 
OR: 0.18, 95% CI: 0.06 to 0.55 
OR: 6.2, 95% CI: 2.20 to 17.48 
OR: 2.81, 95% CI: 1.02 to 7.75 
OR: 27.18, 95% CI: 3.14 to 235.02
Ding et al. (36), 2016 PCOS Pregnancy 
Ovulation 
Miscarriage 
Number of follicles
Late CC vs. Early CC Mature follicles/
cycle
MD: 1.82, 95% CI: 0.86 to 2.78
Farquhar et al. (19), 
2012 
CC resistant PCOS Live birth 
Pregnancy 
Ovulation 
Miscarriage 
Multiple pregnancy 
OHSS Costs
LOD vs. CC+metformin 
LOD vs. CC+metformin 
Live birth/woman 
Costs
OR: 0.44, 95% CI: 0.24 to 0.82 
MD: 3711.3, 95% CI: 3585.17 
to 3837.43
Gill et al. (33), 2014 CC resistant PCOS,  
reproductive age
Pregnancy 
Ovulation 
CC+metformin vs. CC 
CC+metformin vs. CC
Ovulation/woman 
Pregnancy/woman
Higher in CC+metformin 
Higher in CC+metformin
Palomba et al. (24), 
2009
PCOS Live birth 
Pregnancy 
Ovulation 
Miscarriage 
Adverse  events 
Metformin vs. CC+metformin  
Metformin vs. CC+metformin  
Metformin vs. CC+metformin  
Live birth/woman 
Ovulation/woman 
Pregnancy/woman
OR: 0.23, 95% CI: 0.13 to 0.40 
OR: 0.23, 95% CI: 0.15 to 0.34 
OR: 0.23, 95% CI: 0.14 to 0.37
Siebert et al. (28), 2012 PCOS (therapy naïve) Live birth 
Pregnancy 
Ovulation
Metformin vs. CC 
Metformin vs. CC 
CC+metformin vs. CC 
CC+metformin vs. CC 
Live birth/woman 
Ovulation/woman 
Ovulation/woman 
Pregnancy/woman
OR: 0.48, 95% CI: 0.31 to 0.73
OR: 0.48, 95% CI: 0.41 to 0.57
OR: 1.6, 95% CI: 1.2 to 2.1 
OR: 1.3, 95% CI: 1.0 to 1.6
Tang et al. (41), 2012 PCOS Live birth 
Pregnancy 
Ovulation 
Miscarriage 
Multiple pregnancy 
Menstrual frequency
Metformin vs. CC (BMI≥ 30) 
Metformin vs. CC (BMI ≥ 30) 
CC+metformin vs. CC (CC resistant PCOS) 
CC+metformin vs. CC (BMI<30)
CC+metformin vs. CC (BMI≥30)
 Metformin vs. CC (BMI ≥ 30) 
Metformin vs. CC (BMI <30)
CC+metformin vs. CC CC+metformin vs. 
CC (BMI ≥30)
CC+metformin vs. CC 
CC+metformin vs. CC
Live birth/woman 
Ovulation/woman 
Ovulation/woman 
Ovulation/woman 
Ovulation/woman 
Pregnancy/woman 
Pregnancy/woman 
Pregnancy/woman 
Pregnancy/woman 
Side effects  
Side effects (GIT) 
OR: 0.3, 95% CI: 0.17 to 0.52 
OR: 0.43, 95% CI: 0.36 to  0.51 
OR: 4.86, 95% CI: 2.43 to 9.74 
OR: 1.75, 95% CI: 1.27 to 2.39 
OR: 1.78, 95% CI: 1.51 to  2.1 
OR: 0.34, 95% CI: 0.21 to 0.55 
OR: 1.94, 95% CI: 1.19 to 3.16 
OR: 1.51, 95% CI: 1.17 to 1.96 
OR: 1.76, 95% CI: 1.26 to 2.47 
OR: 3.31, 95% CI: 2.11 to 5.20 
OR: 3.4, 95% CI: 2.08 to 5.54
Thakker et al. (47), 
2015
PCOS Live birth
Ovulation 
Miscarriage, 
Multiple pregnancy 
OHSS 
Menstrual regularity
NAC vs. Placebo (CC resistant PCOS) 
NAC vs. Placebo (CC resistant PCOS) 
NAC vs. Placebo (CC resistant PCOS)
Live birth/woman 
Ovulation/woman 
Pregnancy/woman
OR: 3.0, 95% CI: 1.05 to 8.6 
OR: 8.4, 95% CI: 4.5 to 15.67 
OR: 4.83, 95% CI: 2.30 to 10.13
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Table 1: Continued
Xiao et al. (30), 2012 PCOS, <35 years Pregnancy 
Ovulation 
Miscarriage
Metformin vs. CC Metformin+CC vs. CC Ovulation/woman 
Pregnancy/woman
OR: 0.48, 95% CI: 0.26 to 0.87 
OR: 1.56, 95% CI: 1.16 to 2.08
Insulin sensitizers
Tang et al. (41), 2012 PCOS Live birth 
Clinical pregnancy 
Ovulation 
Miscarriage 
Multiple pregnancy 
Menstrual frequency
Metformin vs. Placebo 
Metformin vs. Placebo (BMI < 30) 
Metformin vs. Placebo (BMI ≥30) 
Metformin vs. Placebo (BMI<30)
Metformin vs. Placebo 
Metformin vs. Placebo 
Metformin vs. Placebo
Side effects (GIT)
Menstrual frequency 
Menstrual frequency
Pregnancy/woman
Menstrual frequency
Ovulation/woman
Pregnancy/woman
OR: 4.27, 95% CI: 2.4 to 7.59 
OR: 21.15, 95% CI: 1.01 to 445.0 
OR: 1.57, 95% CI: 1.03 to 2.41 
OR: 2.35, 95% CI: 1.44 to 3.82 
OR: 1.72, 95% CI: 1.14 to 2.61 
OR: 1.81, 95% CI: 1.13 to 2.93 
OR: 2.31, 95% CI: 1.52 to 3.51
Feng et al. (52), 2015 PCOS,  pregnant and  
took metformin to get 
conception
GDM, 
PE, 
Miscarriage, 
Premature delivery
Metformin during pregnancy vs. Placebo 
Metformin during pregnancy vs. Placebo
Miscarriage 
Preterm birth
RR: 0.32, 95% CI: 0.19 to 0.56 
RR: 0.4, 95% CI: 0.18 to 0.91
Tan et al. (58), 2016 PCOS and pregnant GDM, 
PIH/PE, 
Miscarriage 
Preterm delivery 
Fetal abnormality, 
Fetal birth weight
Metformin during pregnancy vs. Placebo
Metformin during pregnancy vs. Placebo 
Metformin during pregnancy vs. Placebo 
Metformin during pregnancy vs. Placebo 
(Non RCTs) 
Metformin during pregnancy vs. Placebo 
(Non RCTs)
GDM 
Miscarriage 
Preterm birth 
GDM
PIH/PE
OR: 0.28, 95% CI: 0.10 to 0.75 
OR: 0.20, 95% CI: 0.12 to 0.31 
OR: 0.33, 95% CI: 0.18 to 0.60 
OR: 0.14, 95% CI: 0.09 to 0.24 
OR: 0.28, 95% CI: 0.16 to 0.48
Zhuo et al. (54),  2014 PCOS and pregnant GDM Metformin during pregnancy vs. Placebo GDM OR: 0.19, 95% CI: 0.13 to 0.27
Zeng et al. (53), 2016 PCOS and pregnant Live birth 
Miscarriage 
Preterm delivery 
GDM 
PIH/PE IUGR 
Fetal malformation 
Neonatal death 
Macrosomia
Metformin during pregnancy vs. Placebo 
Metformin during pregnancy vs. Placebo 
Metformin during pregnancy vs. Placebo 
Metformin during pregnancy vs. Placebo 
Metformin during pregnancy vs. Placebo 
Metformin during pregnancy vs. Placebo
GDM 
IUGR 
Live birth/woman 
Miscarriage
PIH/PE 
Preterm birth
OR: 0.02, 95% CI: 0.14 to 0.87 
OR: 0.17, 95% CI: 0.08 to 0.33 
OR: 5.23, 95% CI: 3.12 to 8.75 
OR: 0.19, 95% CI: 0.12 to 0.28 
OR: 0.22, 95% CI: 0.13 to 0.38 
OR: 0.37, 95% CI: 0.20 to 0.68
Li et al. (22),  2011 PCOS Pregnancy
Ovulation 
Menstrual regularity
Metformin vs. Thiazolidinediones (3 months 
duration) 
Metformin vs. Thiazolidinediones (6 months 
duration)
Side effects  
Side effects 
OR: 8.88, 95% CI: 3.54 to 22.27 
OR: 12.22, 95% CI: 3.53 to 
42.31 
Thakker et al.(47), 2015 PCOS Live birth 
Ovulation 
Miscarriage, 
Multiple pregnancy 
OHSS 
Menstrual  regularity
NAC vs. Metformin 
NAC vs. Metformin Ovulation/woman 
Pregnancy/woman
OR: 0.13, 95% CI: 0.08 to 0.22 
OR: 0.4, 95% CI: 0.23 to 0.71
Al Khalifah et al. (34), 
2016
Adolescents with PCOS 
(11-19 year old)
Menstrual regulation OCP vs. Metformin Menstrual 
frequency
MD; 0.27, 95% CI: -0.33 to 
-0.21
Fang et al. (37), 2017 PCOS Dominant follicles 
Menstrual regularity
Vitamin D + metformin vs. Metformin Menstrual 
frequency
OR: 1.85, 95% CI: 1.01 to 3.39
Pundir et al. (38), 2017 PCOS Live birth
Clinical pregnancy 
Ovulation 
Miscarriage 
Menstrual regulation 
Inositol vs. Placebo 
Inositol vs. Placebo 
Pioglitazone vs. Placebo 
Roziglitazone vs. Placebo
Ovulation/woman 
Menstrual frequency 
Menstrual frequency 
Menstrual frequency
RR: 2.3, 95% CI: 1.1 to 4.7 
RR: 6.8, 95% CI: 2.8 to 16.6 
OR: 8.88, 95% CI: 2.35 to 33.61 
OR: 5.59, 95% CI: 2.20 to 14.19
BMI; Body mass index, CC; Clomiphene citrate, DEX; Dexamethasone, GDM; Gestational diabetes mellitus, GIT; Gastrointestinal tract, IUGR; Intra-uterine growth restriction, IUI; Intra 
uterine insemination, LOD; Laparoscopic ovarian drilling, MD; Mean difference, NAC; N-acetyl cysteine, OCP; Oral contraceptive pills, OHSS; Ovarian hyper-stimulation syndrome, 
OR: Odds ratio, PCOS; Polycystic ovary syndrome, PIH/PE; Pregnancy induced hypertension/Preeclampsia, RCT; Randomized controlled trial, rFSH: Recombinant follicle stimulating 
hormone, RR; Risk ratio, SMD; Standardized mean difference, and WHO; World Health Organization.     
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Table 2: Results of their interventions
Gonadotrophins
Bordewijk et al. (45), 
2017
PCOS and 
anovulatory women
Live birth 
Clinical pregnancy 
Ovulation 
Multiple pregnancy 
Miscarriage 
OHSS 
Adverse effects 
FSH+metformin vs. FSH in PCOS 
resistant 
FSH+metformin vs. FSH in PCOS 
resistant
Live birth/woman 
Pregnancy/woman
OR: 2.31, 95% CI: 1.23 to 4.34 
OR: 2.46, 95% CI: 1.36 to 4.46   
Farquhar et al. (19), 2012 CC resistant PCOS Live birth 
Pregnancy 
Ovulation 
Miscarriage 
Multiple  pregnancy 
OHSS 
Costs
LOD vs. Gonadotrophins long-term 
LOD vs. Gonadotrophins short-term 
LOD vs. Gonadotrophins
Costs 
Costs 
Multiple pregnancy
MD: -2235.0, 95% CI: -4433.16 to -36.84 
MD: -1115.75, 95% CI: -1309.72 to -921.77 
OR: 0.13, 95% CI: 0.03 to 0.52
Moazami Goudarzi et al. 
(23), 2014
CC-resistant PCOS Live birth 
Pregnancy 
Miscarriage 
Multiple pregnancies
LOD vs. Gonadotropins 
LOD vs. Gonadotropins
Live birth/woman 
Multiple pregnancy
OR: 0.446, 95% CI: 0.269 to 0.74 
OR: 0.127, 95% CI: 0.028 to 0.579
Palomba et al. (40),  2014 PCOS Live birth 
Pregnancy 
Miscarriage 
Multiple pregnancy 
OHSS 
Gonadotrophins+metformin vs. 
Gonadotrophins in OI
Gonadotrophins+metformin vs. 
Gonadotrophins in OI 
Gonadotrophins+metformin vs. 
Gonadotrophins in OI 
Gonadotrophins+metformin vs. 
Gonadotrophins in OI 
Gonadotrophins+metformin vs. 
Gonadotrophins in OI
Live birth/woman 
Pregnancy/woman 
Cancellation/cycle 
Gonadotrophins units 
Stimulation length
OR: 1.94, 95% CI: 1.10 to 3.44 
OR: 2.25, 95% CI: 1.50 to 3.38 
OR: 0.41, 95% CI: 0.24 to 0.72 
MD: 306.62, 95% CI: -500.02 to -113.22 
MD: -3.28, 95% CI: -6.23 to -0.32
Weiss et al. (29), 2015 CC-resistant ± 
failure PCOS 
Women treated 
with prior 
metformin use 
+/-  CC 
Women with prior 
electro cautery of 
ovaries.
Live birth 
Clinical pregnancy 
Miscarriage 
Multiple pregnancy 
OHSS
rFSH vs. All urinary gonadotrophins 
rFSH vs. HMG
rFSH vs. uFSH 
rFSH vs. All urinary gonadotrophins 
rFSH vs. HMG 
rFSH vs. uFSH
Gonadotrophins units 
Gonadotrophins units 
Gonadotrophins units 
Stimulation length 
Stimulation length 
Stimulation length
MD: -105.44, 95% CI: -154.21, -56.68 
MD: -283.94, 95% CI: -449.10 to -118.78 
MD: -88.4, 95% CI: -139.44 to -37.36 
MD: -0.66, 95% CI: -1.04 to -0.28 
MD: -2.28, 95% CI: -3.49 to -1.07 
MD: -0.49, 95% CI: -0.88 to -0.09
Laparoscopic ovarian drilling (LOD)
Farquhar et al. (19), 2012 CC resistant PCOS Live birth 
Pregnancy 
Ovulation 
Miscarriage 
Multiple pregnancy 
OHSS 
Costs
 LOD vs. Metformin 
LOD vs. other medical treatments
Pregnancy/woman 
Multiple pregnancy
OR: 2.47, 95% CI: 1.05 to 5.81 
OR: 0.21, 95% CI: 0.08 to 0.58
Baghdadi et a. (56), 2012 CC resistant  PCOS Pregnancy 
Ovulation
Lean vs. obese PCOS 
Lean vs. Obese PCOS 
Lean vs. Obese PCOS 
Lean vs. Obese PCOS
Ovulation/cycle 
Ovulation/woman 
Pregnancy/cycle 
Pregnancy/woman
RR: 1.90, 95% CI: 1.46 to 2.48 
RR: 1.43, 95% CI: 1.22 to 1.66 
RR: 4.14, 95% CI: 2.08 to 8.23 
RR: 1.73, 95% CI: 1.39 to 2.17
IUI/IVF/ICSI related interventions
Luo et al. (57), 2014 PCOS undergoing 
COS/IUI
Live birth 
Clinical pregnancy 
Miscarriage
GnRH antagonist +IUI vs. Control IUI 
GnRH antagonist +IUI vs. Control IUI 
GnRH antagonist +IUI vs. Control IUI
LH 
Premature lutenization rate
Progesterone 
MD: 4.6, 95% CI: 0.9 to 8.31 
OR: 4.36, 95% CI: 2.15 to 8.84 
MD: 0.31, 95% CI: 0.24 to 0.37
Kollman et al. (18), 2016 PCOS Live birth/ ongoing 
pregnancy 
Clinical pregnancy 
Miscarriage 
OHSS
Inositol vs. Placebo 
IVF 
Myo-inositol vs. D-chiro-inositol
Antagonist vs. Agonist 
Mannitol vs. Placebo
Pregnancy/woman 
Pregnancy/woman 
OHSS 
OHSS
RR: 1.41, 95% CI: 1.05 to 1.89 
RR: 2.86, 95% CI: 1.14 to 7.16 
RR: 0.63, 95% CI: 0.49 to 0.80 
RR: 0.54, 95% CI: 0.39 to 0.77
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Palomba et al. (59), 2013 PCOS undergoing 
IVF cycles
Live birth Pregnancy 
Miscarriage
OHSS 
Gonadotrophins+metformin vs. 
Gonadotrophins (Metformin stopping 
time until 12 weeks of gestation) 
Gonadotrophins+metformin vs. 
Gonadotrophins  
Gonadotrophins+metformin vs. 
Gonadotrophins (Metformin stopping 
time until 12 weeks of gestation) 
Gonadotrophins+metformin vs. 
Gonadotrophins (Pretreatment length 
effect for long-term >3 weeks) 
Gonadotrophins+metformin vs. 
Gonadotrophins (Pretreatment length 
effect for short-term ≤ 3 weeks) 
Gonadotrophins+metformin vs. 
Gonadotrophins (Metformin stopping 
time until oocyte retrieval, ET and 
HCG injection) 
Gonadotrophins+metformin vs. 
Gonadotrophins (no pretreatment 
period) 
Gonadotrophins+metformin vs. 
Gonadotrophins (higher dose >1000 
mg daily) 
Gonadotrophins+metformin vs. 
Gonadotrophins (lower dose <=1000 
mg/daily) 
Gonadotrophins+metformin 
vs. Gonadotrophins 
Gonadotrophins+metformin vs. 
Gonadotrophins 
Gonadotrophins+metformin vs. 
Gonadotrophins (higher dose >1000 
mg daily) 
Gonadotrophins+metformin vs. 
Gonadotrophins (Pretreatment length 
effect for long-term >3 weeks) 
Gonadotrophins+metformin vs. 
Gonadotrophins (Metformin stopping 
time until pregnancy test) 
Gonadotrophins+metformin vs. 
Gonadotrophins (Pretreatment length 
effect for long-term >3 weeks) 
Gonadotrophins+metformin vs. 
Gonadotrophins (higher dose > 1000 
mg daily) 
Gonadotrophins+metformin vs. 
Gonadotrophins (Metformin stopping 
time until pregnancy test) 
Gonadotrophins+metformin vs. 
Gonadotrophins (lower dose <=1000 
mg/daily)
Live birth/woman 
Miscarriage 
Miscarriage 
Miscarriage 
OHSS 
OHSS 
OHSS 
OHSS 
OHSS 
OHSS 
Oocyte number retrieved 
Oocyte number retrieved 
Oocyte number retrieved 
Oocyte number retrieved 
Implantation/embryo 
Implantation/embryo 
Stimulation length 
Gonadotrophins units 
OR: 75.6, 95% CI: 8.03 to 711.5 
OR: 0.50, 95% CI: 0.30 to 0.83 
OR: 0.08, 95% CI: 0.02 to 0.39 
OR: 0.41, 95% CI: 0.21 to 0.78 
OR: 0.20, 95% CI: 0.07 to 0.54 
OR: 0.22, 95% CI: 0.11 to 0.42 
OR: 0.14, 95% CI: 0.05 to 0.38 
OR: 0.40, 95% CI: 0.20 to 0.80 
OR: 0.15, 95% CI: 0.06 to 0.38 
OR: 0.27, 95% CI: 0.16 to 0.46 
WMD: -1.11, 95% CI: -1.86 to 
-0.36 
WMD: -1.16, 95% CI: -1.96 to 
-0.37 
WMD: -1.45, 95% CI: -2.37 to 
-0.53 
WMD: -1.32, 95% CI:  -2.40 to 
-0.23 
OR: 0.28, 95% CI: 0.12 to 0.62 
OR: 1.42, 95% CI: 1.24 to 2.75 
WMD: 0.85, 95% CI: 0.02 to 1.68 
WMD: -326.84, 95% CI: -505.99 
to -147.69 
Huang et al. (21), 2015 PCOS undergoing 
IVF/ICSI in non-
donor cycles
Live birth 
Clinical pregnancy 
Miscarriage 
Multiple pregnancy 
OHSS
Metformin vs. Placebo OHSS RR: 0.44; 95%CI 0.26 to 0.77
Tso et al. (42), 2014 PCOS and of 
reproductive age 
undergoing IVF 
or ICSI
Live birth 
Clinical pregnancy 
Miscarriage 
OHSS 
Side effects
Metformin vs. Placebo 
Metformin vs. Placebo 
Metformin vs. Placebo 
Metformin vs. Placebo (long 
protocol GnRH agonist)
Pregnancy/woman 
Side effects  
OHSS 
OHSS 
OR: 1.52, 95% CI: 1.07 to 2.15
OR: 4.49, 95% CI: 1.88 to 10.72
OR: 0.29, 95% CI: 0.18 to 0.49
OR: 0.29, 95% CI: 0.16 to 0.51
Pundir et al. (26), 2012 PCOS  undergoing 
IVF with or 
without ICSI
Live birth
Clinical pregnancy
Ongoing pregnancy
Miscarriage
OHSS
GnRH antagonist vs. Agonist Gonadotrophins units WMD:  -0.28, 95% CI: -0.43 to -0.13)
GnRH antagonist vs. Agonist Moderate and severe OHSS RR: 0.59, 95% CI: 0.45 to 0.76
GnRH antagonist vs. Agonist OHSS (moderate & severe) RR: 0.60, 95% CI: 0.48 to 0.76
GnRH antagonist vs. Agonist Stimulation length WMD: -0.74, 95% CI: -1.12 to -0.36
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Siristatidis et al. (50), 
2015
PCOS, PCO  and 
control undergoing 
IVM
Live birth
Clinical pregnancy
Miscarriage
Oocyte maturation
IVM in (PCOS vs. Control) Cancellation/cycle OR: 0.15, 95% CI: 0.05 to 0.44
IVM in (PCOS vs. Non PCOS) Cancellation/cycle OR: 0.18, 95% CI: 0.06 to 0.47
IVM in (PCOS vs. PCO) Cancellation/cycle OR: 0.25, 95% CI: 0.07 to 0.92
IVM in (PCOS vs. Non PCOS) Implantation/embryo OR: 1.73, 95% CI: 1.06 to 2.81
IVM in (PCOS vs. Control) Maturation/oocyte OR: 0.74, 95% CI: 0.59 to 0.93
IVM in (PCOS vs. Control) Pregnancy/cycle OR: 3.09, 95% CI: 1.46 to 6.53
IVM in (PCOS vs. Non-PCOS) Pregnancy/cycle OR: 2.23, 95% CI: 1.45 to 3.43
IVM in (PCOS vs. Control) Pregnancy/woman OR: 3.29, 95% CI: 1.42 to 7.62
IVM in (PCOS vs. Non PCOS) Pregnancy/woman OR: 2.37, 95% CI: 1.53 to 3.68 
Xiao et al. (31), 2013 PCOS Clinical pregnancy
Miscarriage
OHSS  
GnRH antagonist vs. GnRH agonist Moderate-severe OHSS OR: 0.36, 95% CI: 0.25 to 0.52
GnRH antagonist vs. GnRH agonist Stimulation length Shorter in GnRH antagonist group
CC; Clomiphene citrate, COS; Controlled ovarian stimulation, ET; Embryo transfer, FSH: Follicle stimulating hormone, GnRH; Gonadotrophins releasing hormone, HCG; Human 
chorionic gonadotrophin, HMG; Human menopausal gonadotrophin, ICSI; Intra cytoplasmic sperm injection, IUI; Intra uterine insemination, IVF; In vitro fertilization, IVM; In vitro 
maturation, LH; Luteinizing hormone, LOD; Laparoscopic ovarian drilling, MD; Mean difference, OHSS; Ovarian hyper-stimulation syndrome, OI; Ovulation induction, OR; Odds ratio, 
PCOS; Polycystic ovary syndrome, rFSH; Recombinant follicle stimulating hormone, RR; Risk ratio, uFSH; Urinary follicle stimulating hormone, and WMD; Weighted mean difference   
Clomiphene citrate
Seventeen reviews, [seven high quality (19, 39, 41, 46-
49), six moderate quality (16, 20, 24, 27, 32, 38) and four 
low quality (28, 30, 33, 36)] assessed interventions that 
contained CC, comprising a total of 203 trials with 26 731 
participants. One review assessed CC versus LOD (19). 
One review assessed early follicular versus late luteal CC 
administration (36). The remaining 14 reviews assessed 
CC ± other OI drugs such as metformin, inositol, N-acetyl 
cysteine (NAC) and others versus other OI drugs, includ-
ing CC. The populations studied were women with PCOS 
who were treatment-naïve (27), CC resistant (19, 32, 33) 
and women with PCOS who were treatment-naïve ± CC 
resistant PCOS or unknown treatment status. 
The meta-analyses reported in overall women with 
PCOS that CC compared to placebo had statistically 
higher pregnancy and ovulation (46). Early follicular CC 
had higher pregnancy than late luteal CC (46) but with 
less mature follicles (36). Higher live birth, pregnancy, 
and ovulation resulted after CC compared to metformin 
mainly in women with BMI ≥30 kg/m2 (28, 30, 41) while 
metformin resulted in higher pregnancy than CC in wom-
en with BMI <30 kg/m2 (41). CC plus metformin was of 
more benefit than CC or metformin alone with regards to 
live birth (24), pregnancy and ovulation, but had higher 
gastrointestinal side effects (24, 28, 30, 33, 41). Higher 
live birth and pregnancy resulted after gonadotrophins 
compared to CC and 10 days of CC compared to 5 days of 
CC, respectively (46).
In women with CC resistant PCOS, gonadotrophins 
resulted in statistically higher live birth, pregnancy and 
ovulation than CC plus metformin (32, 46) which, in turn, 
resulted in higher live birth than LOD (19). In the same 
population of women, the addition of dexamethasone, 
NAC or contraceptive pills to CC resulted in higher live 
births, pregnancy and ovulation than CC alone (46, 47). 
Furthermore, the addition of metformin to CC resulted in 
more favourable outcomes compared with the addition of 
NAC with regards to pregnancy and ovulation. However, 
the cost of treatment was greater for gonadotrophins fol-
lowed by LOD then CC plus metformin (19).
Gonadotrophins
Ten reviews [six high quality (19, 29, 39, 45, 46, 49) and 
four moderate quality (23, 32, 40, 59)] assessed interven-
tions containing gonadotrophins, which comprised 146 
trials with 18 379 participants. Two reviews assessed gon-
adotrophins versus LOD (19, 23). Three reviews assessed 
the effectiveness of adding metformin to gonadotrophins 
during OI (40, 45) and IVF (59). Two reviews assessed 
gonadotrophins versus anti-oestrogens ± adjunctive drugs 
(32, 46). Two reviews assessed gonadotrophins versus 
aromatase inhibitors (39, 49). One review assessed the ef-
fectiveness of different types of gonadotrophins (29). The 
populations studied were women with CC resistant PCOS 
(19, 23, 29, 32) and women who were treatment-naïve ± 
CC resistant PCOS women or unknown treatment status.
The meta-analyses reported that in women with CC 
resistant PCOS, gonadotrophins resulted in statistical-
ly higher live births, multiple pregnancies, and costs of 
short- and long-term treatment in comparison to LOD 
(19, 23) and higher live births, pregnancy and ovulation 
in comparison to CC ± metformin (32, 46), but lower 
pregnancy in comparison to letrozole (39). Adding met-
formin to gonadotrophins, compared to gonadotrophins 
alone, resulted in higher live birth and pregnancy in OI 
(40, 45) and higher live birth, implantation rate, lower 
miscarriage, ovarian hyperstimulation syndrome (OHSS) 
and number of oocyte retrieved in IVF (59). Recombinant 
follicle stimulating hormone (FT.) resulted in lower dose 
and stimulation duration than other urinary gonadotro-
phins in OI (29).
Insulin sensitizers
Thirty reviews (12 reviews of high quality (18, 19, 34, 
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39, 41, 42, 44-49), 13 reviews of moderate quality (16, 
21, 22, 24, 25, 32, 35, 37, 38, 40, 53, 54, 59) and five 
reviews of low quality (28, 30, 33, 52, 58) assessed in-
terventions that contained insulin sensitizers comprising 
398 trials with 45 031 participants. Four reviews assessed 
metformin versus placebo (18, 21, 41, 42). Four reviews 
assessed metformin during pregnancy (52-54, 58). One 
review assessed the effect of pre-gestational metformin 
on risk of miscarriage (25). One review assessed rozigli-
tazone, plioglitazone, and D-chiro-inositol versus placebo 
(41). One review assessed metformin versus thiazolidine-
diones (22). One review assessed LOD versus metformin 
(19). One review assessed NAC versus placebo or met-
formin (47). One review assessed oral contraceptive pills 
versus metformin (34). One review assessed the benefit 
of adding vitamin D to metformin (37).Three reviews had 
CC resistant PCOS women as participants (19, 32, 33) 
while the others did not clarify the treatment status.
The meta-analyses reported that, overall in women with 
PCOS, metformin resulted in higher live births, pregnancy, 
and gastrointestinal side effects with lower OHSS than pla-
cebo when used in addition to IVF (18, 21, 42) and higher 
pregnancy, ovulation, side effects and menstrual frequency 
in OI (41). Metformin had higher gastrointestinal side ef-
fects than thiazolidinediones (22). In women with CC re-
sistant PCOS, NAC resulted in higher live births, pregnancy 
and ovulation than placebo, but lower pregnancy and ovu-
lation than metformin (47). Oral contraceptive pills were 
better than metformin in improving menstrual frequency 
(34). Adding vitamin D to metformin improved menstrual 
frequency than metformin alone (37). Inositol resulted in 
higher pregnancy than placebo with more benefit of myo-
inositol over D-chiro inositol in IVF (18), while inositol re-
sulted in higher ovulation than placebo in OI. Roziglitaone, 
pioglitazone and inositol improved menstrual frequency in 
OI (38). In women with PCOS who became pregnant, met-
formin intake during pregnancy resulted in higher live birth 
and lower miscarriage, preterm labour, gestational hyper-
tension, preeclampsia, gestational diabetes and intrauterine 
growth retardation (52-54, 58).
Laparoscopic ovarian drilling
Six reviews [four high quality (19, 32, 39, 49) and two 
moderate quality (23, 56)] assessed ovarian ablation ther-
apy and LOD as an intervention in PCOS comprising 97 
trials with 13 617 participants. Three reviews had partici-
pants as CC resistant PCOS (19, 23, 56).
The meta-analyses reported that LOD resulted in lower 
live births than CC plus metformin and gonadotrophins, 
respectively (19, 23), higher pregnancy than metformin 
alone (19), lower ovulation than letrozole (49), higher 
costs than CC plus metformin but lower than gonadotro-
phins (19) and lower multiple pregnancy rate than other 
medical treatments (19). Pregnancy and ovulation were 
higher in lean women (BMI <25 kg/m2) with CC resistant 
PCOS than in overweight and obese women (BMI ≥25 
kg/m2) undergoing LOD (56). 
Intrauterine insemination, in vitro fertilization, intra-
cytoplasmic sperm injection related interventions
Nine reviews [three high quality (17, 18, 42)] and six 
moderate quality (21, 26, 31, 50, 57, 59) assessed dif-
ferent interventions in women with PCOS undergoing 
assisted reproductive techniques [intrauterine insemina-
tion (IUI), IVF/ICSI] comprising 126 trials with 12 298 
participants in eight reviews and 333 cycles in the ninth 
review which did not report on the number of participants 
(57). Three reviews assessed gonadotrophin releasing 
hormone (GnRH) antagonist as an adjuvant interven-
tion in controlled ovarian stimulation plus IUI (57) and 
in comparison with GnRH agonist during IVF/ICSI (26, 
31). Three reviews assessed the effect of metformin dur-
ing IVF/ICSI (21, 42, 59). Two reviews assessed the use 
of IVM (17, 50).
The meta-analyses reported statistically significant re-
sults for lower progesterone, luteinizing hormone (LH) 
and premature luteinisation rate during IUI after GnRH 
antagonist (57) and lesser dose, duration of gonadotro-
phins and OHSS rate after GnRH antagonist during lVF/
ICSI . Metformin compared to placebo in IVF resulted 
in higher live births (18, 59), pregnancy (18, 42), lower 
miscarriage (59), lower OHSS (18, 21, 42, 59), and lower 
oestradiol (E2), gonadotrophin dose and higher implanta-
tion rate (59); however, disadvantages included more, yet 
mild, gastrointestinal side effects (42). Compared to pla-
cebo, inositol resulted in higher pregnancy with better re-
sults after myoinositol than D-Chiro inositol, while man-
nitol resulted in lower OHSS (18). IVM used in women 
with PCOS had higher pregnancy, lower cancelled cycles, 
higher implantation but lower mature oocytes than IVM 
in non-PCOS patients (50).
Other interventions
A low quality review reported that bariatric surgery 
improved menstrual frequency in women with PCOS in 
six trials and 264 participants (51). A high quality review 
reported that statins did not improve menstrual frequency 
or ovulation in women with PCOS not trying to conceive 
in four trials and 244 participants (43). A high quality re-
view (44) assessed the use of antidepressants in women 
with PCOS, and identified no studies reporting on any of 
the primary reproductive outcomes with the exception of 
one RCT that reported on endocrine and metabolic out-
comes between fluoxetine with sibutramine found no sig-
nificant difference between both drugs (61). A moderate 
quality review assessed orlistat versus other anti-obesity 
drugs and found no difference in reproductive outcomes 
(55).
Discussion
We reported the first overview of systematic reviews 
on treatment for reproductive outcomes in women with 
PCOS. This review follows a process of systematic re-
views proposed by the Cochrane collaboration that sum-
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marizes evidence from more than one systematic review 
of different interventions for the same condition (62, 63). 
This type of review can be utilized as a rich source of data 
synthesis for developing and updating guidelines, and 
for health care policy makers. Our overview included 53 
systematic reviews (9 older versions and 44 currently up-
dated articles), 498 studies, and 56 057 participants. The 
quality of most included reviews was moderate to high, 
although the quality of included studies was variable.
Our results align with most current guidelines on PCOS. 
According to many guidelines, treatment of anovulation 
in PCOS should start with lifestyle modification before 
commencing pharmacological agents, especially in obese 
women with BMI >30 kg/m2 (1, 3, 8, 10, 11), The first-
line pharmacological agent is usually CC (2, 3, 11, 64, 65) 
and some guidelines propose letrozole as an alternative 
(1, 8, 10). Our results suggest that, overall, in women with 
PCOS (with or without CC resistance), letrozole resulted 
in higher live birth and clinical pregnancy rates than other 
OI drugs, especially CC. This is consistent with many re-
views and RCTs (9, 20, 27, 32, 39, 49, 66-68), despite the 
fact that letrozole is an off-label drug in OI. Nevertheless, 
the issue of safety in pregnancy for both CC and letrozole 
has not been completely resolved. Most large retrospec-
tive studies found no evidence of any difference between 
these drugs (69). Metformin is recommended in many 
guidelines as an adjunctive treatment with CC in women 
with glucose intolerance and in obese women (1-3, 8, 10), 
while the National Institute for Health and Clinical Excel-
lence Guidance (NICE) recommended metformin alone or 
with CC as a first-line treatment (11). Our results suggest 
that, overall, in women with PCOS, CC plus metformin 
also resulted in in better reproductive outcomes than CC 
or metformin alone. The Australian National Health and 
Medical Research Council (NHMRC) evidence-based 
guidelines suggested that it is acceptable to use gonado-
trophins as a first-line treatment (8). Our results suggest 
that the use of gonadotrophins resulted in higher live birth 
and clinical pregnancy rates than CC, overall, in women 
with PCOS.
CC is usually used for six months, which is recom-
mended by many guidelines (1, 8, 11). After that, wom-
en are considered to be CC resistant, which necessitates 
a second-line treatment. Most fertility guidelines recom-
mend low dose gonadotrophins or LOD as a second-line 
treatment (1-3, 8, 10, 11). CC plus metformin was also 
recommended by some guidelines, if not already used 
as a first-line treatment (8, 11). Gonadotrophins have 
the disadvantage of cost and increased rates of multi-
ple pregnancies, while LOD has a risk with anaesthesia, 
decreased ovarian reserve, and the need to use adjuvant 
drugs for OI after surgery (3). Our results suggest that, 
in women with CC resistant PCOS, gonadotrophins re-
sulted in better reproductive outcomes than many OI 
drugs with the disadvantages of increased multiple preg-
nancies and increased cost (19, 23, 32, 46). We found 
that women who used gonadotrophins had higher live 
birth than those who were prescribed CC plus metformin 
or LOD respectively, and higher clinical pregnancy and 
ovulation rates than CC plus metformin. CC plus met-
formin resulted in higher live birth rate and lower cost 
than LOD. Gonadotrophins are more expensive than 
LOD. LOD has the advantage of lower rates of multi-
ple pregnancies compared to other interventions, such 
as gonadotrophins, in CC resistant PCOS (19). LOD in 
lean women seem to have better reproductive outcomes 
than in overweight and obese women. 
Current recommendations state that IVF should be used 
in case of CC failure, which is defined by failure of con-
ception after 6-9 months (1, 11). Our results support the 
current evidence for use of GnRH antagonists and addi-
tion of metformin to GnRH agonist to decrease OHSS (1). 
There is lack of data on use of IVM in PCOS (1), which 
is reported by one of included reviews (17). Another re-
view by the same author reported higher pregnancy and 
implantation rates with lower cancellation rate in women 
with PCOS undergoing IVM compared to IVM in non-
PCOS women (50).
Despite the large number of reviews and RCTs that have 
been conducted assessing different treatments for man-
agement of reproductive outcomes in women with PCOS, 
there are still a considerable number of research gaps. 
Recently, the international evidence-based guideline for 
the assessment and management of PCOS has issued new 
recommendations for the diagnosis and management of 
PCOS(70). These guidelines state that letrozole should 
be considered first-line pharmacological treatment for OI 
in women with PCOS with anovulatory infertility and no 
other infertility factors to improve ovulation, pregnancy 
and live birth rates. This is consistent with our results in 
this overview. They also stated that inositol (in any form) 
should currently be considered an experimental therapy in 
PCOS, with emerging evidence on efficacy highlighting 
the need for further research (70). Furthermore, research 
on the possible reasons for CC resistance and failure uti-
lizing unified definitions is needed. This is particularly 
relevant given that some recent reviews revealed that the 
antiestrogenic effect of CC, specifically on endometrial 
tissue, is not enough rationale for resistance and failure 
(66). Furthermore, a recent crossover RCT found that 
there is no difference in clinical pregnancy and live birth 
rates between CC and letrozole when used as a second 
line treatment in women who failed to ovulate or con-
ceive with CC or letrozole as first line of treatment (9). 
It is also important to note that a thorough study of the 
cost effectiveness of any of these treatments has not been 
performed, particularly in low income countries. Further 
investigation of metformin with regards to its cost effec-
tiveness, safety, and effectiveness in non-obese women is 
also needed (1, 8). There is also a lack of data relating 
to the comparison between the use of LOD and medical 
treatment as a first line treatment, and the minimum ef-
ficient dose of LOD to induce ovulation without affecting 
ovarian reserve (1, 3, 11).
Limitations include our search strategy with reviews pub-
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lished from 2009 onwards, coinciding with the PRISMA 
statement publication for conducting systematic reviews. 
While this would miss earlier reviews, later included re-
views would be likely to be of higher quality and aligned 
with the PRISMA statement. We applied language restric-
tions including only articles in English, which might lead 
to bias in exclusion of other languages. We found insuf-
ficient data on the quality of included studies in each re-
view. We did not perform a quality assessment of each 
of the individual trials within each systematic review 
and relied instead on the judgement of the authors which 
varied from cursory to comprehensive; although we note 
that performing a quality assessment of 498 total studies 
would have been an extensive task. We note that the ac-
tual effect of different treatments in each treatment status 
and PCOS phenotypes is still unclear. We also note wide 
variability in the definition of outcomes across reviews 
and included studies. For instance, although pregnancy 
was reported as clinical pregnancy in most included re-
views, ongoing pregnancy was reported in some reviews 
(26, 45) and pregnancy was not predefined in others (22, 
24, 36, 40, 51, 56). The definition of clinical pregnancy 
varied across the included studies within each review.
Conclusion
We report here a significant contribution to the litera-
ture in the overview and synthesis of systematic reviews 
that assessed medical and surgical treatments for repro-
ductive outcomes in women with PCOS. In agreement 
with most recent international guidelines on management 
of PCOS, letrozole was superior to other OI agents as a 
first-line pharmacological treatment with gonadotrophins 
a second-line pharmacological treatment for anovulatory 
women with PCOS.
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